Cooley LLP has a strong track record advising global life sciences and healthcare companies, with many of the well-experienced team members leveraging advanced degrees in biology, pharmaceuticals and biotechnology. Key practice strengths include cross-border transactions, IPOs, M&A and licensing matters, as well as assisting investors and investment banks on strategic transactions. Shanghai-based Yiming Liu is well-regarded among leading healthcare founders, bankers and investors for his expertise in private financings, capital markets transactions, M&A and licensing matters. Patrick Loofbourrow splits his time between Singapore and Shanghai, reputed for his corporate practice, frequently acting for biotech and pharmaceutical companies on complex high-value transactions.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Client satisfaction: Billing & efficiency
Client satisfaction: Sector knowledge
Client satisfaction: NPS ®
Testimonials
Collated independently by Legal 500 research team.
- ‘The Cooley team has the broadest coverage in geographic practice and business functions, including financing, IP, human resources, benefits and deal transactions. ’
- ‘Patrick Loofbourrow is outstanding. He's highly professional, responsive, approachable and very thorough. ’
Key clients
- Akeso Inc.
- Angitia
- Asymchem Laboratories Inc.
- AusperBio
- Beihai Biotech
- Chimagen Biosciences
- Earendil Labs
- Evopoint Biosciences Co., Ltd.
- Foreseen Biotechnology
- Harbour BioMed
- Hengrui Pharmaceuticals
- Inmagene Biopharmaceuticals
Work highlights
Advised FutureGen on its US$1.8 billion license agreement with AbbVie to develop FG-M701, a next-generation TL1A antibody for the treatment of IBD currently in preclinical development.
Advised Earendil Labs on its US$1.8 billion license agreement with Sanofi for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases.
Advised Evopoint on its US$1.34 billion exclusive license agreement with Astellas Pharma Inc. for XNW27011, a novel investigational clinical-stage antibody-drug conjugate (ADC) targeting CLDN18.2.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Ruomu Li
Other key lawyers
Yiming Liu; Patrick Loofbourrow; Freddy Yip